Clinical Trial Update: Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Nexavar (sorafenib) to placebo in locally advanced/metastatic RAI-refractory differentiated thyroid cancer completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Thyroid Neoplasms

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Thyroid Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2013-12-10